These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 24676715)

  • 1. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
    Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
    Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
    Trials; 2011 Jan; 12():3. PubMed ID: 21205325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
    Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
    JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.
    Mariani J; Rosende A; De Abreu M; Gonzalez Villa Monte G; D'Imperio H; Antonietti L; Lemonnier G; de Bonis A; Tajer C
    Ther Adv Cardiovasc Dis; 2020; 14():1753944720912071. PubMed ID: 32186246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
    Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
    Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
    Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
    Wald DS; Wald NJ
    J Eval Clin Pract; 2012 Jun; 18(3):612-5. PubMed ID: 21276141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
    Joseph P; Pais P; Dans AL; Bosch J; Xavier D; Lopez-Jaramillo P; Yusoff K; Santoso A; Talukder S; Gamra H; Yeates K; Lopez PC; Tyrwhitt J; Gao P; Teo K; Yusuf S;
    Am Heart J; 2018 Dec; 206():72-79. PubMed ID: 30342297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
    Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.